FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048663323> ?p ?o ?g. }

• W3048663323 endingPage "1953" @default.
• W3048663323 startingPage "1940" @default.
• W3048663323 abstract "Hematoma is a crucial factor leading to poor prognosis after intracerebral hemorrhage (ICH). Promoting microglial phagocytosis to enhance hematoma resolution may be an important therapeutic target for recovery after ICH. C-C chemokine receptor 4 (CCR4) is important for regulating immune balance in the central nervous system. However, whether CCR4 activation can attenuate hematoma after ICH remains unknown. We aimed to evaluate whether CCL17 (a specific ligand of CCR4) treatment can promote hematoma resolution through CCR4/ERK/Nrf2/CD163 pathway after ICH. A total of 261 adult male CD1 mice were used. Mice were subjected to intrastriatal injection of autologous blood to induce ICH and randomly assigned to receive recombinant CCL17 (rCCL17) or vehicle which was administered intranasally at 1 h after ICH. To elucidate the underlying mechanism, C021, a selective inhibitor of CCR4 and ML385 and a selective inhibitor of Nrf2 were administered 1 h prior to ICH induction. Clustered regularly interspaced short palindromic repeats (CRISPR) knockout for CD163 was administered by intracerebroventricular injection at 48 h before ICH. Brain edema, short- and long-term neurobehavior evaluation, hematoma volume, hemoglobin content, western blot, and immunofluorescence staining were performed. Endogenous CCL17, CCR4, and CD163 expression increased and peaked at 72 h after ICH. CCR4 was expressed by microglia. CCR4 activation with rCCL17 significantly improved neurobehavioral scores and reduced hematoma volume and brain edema compared with vehicle. Moreover, rCCL17 treatment significantly promoted phosphorylation of ERK1/2, increased the expression Nrf2, and upregulated CD163 expression after ICH. The protective effects of rCCL17 were abolished by administration of C021, ML385, and CD163 CRISPR knockout. This study demonstrated that CCR4 activation with rCCL17 promoted hematoma resolution by increasing CD163 expression and CCR4/ERK/Nrf2 pathway activation after ICH, thereby reducing brain edema and improving neurological function. Overall, our study suggests that CCR4 activation may be a potential therapeutic strategy to attenuate hematoma in early brain injury after ICH." @default.
• W3048663323 created "2020-08-18" @default.
• W3048663323 creator A5004014354 @default.
• W3048663323 creator A5010889678 @default.
• W3048663323 creator A5013900535 @default.
• W3048663323 creator A5016467704 @default.
• W3048663323 creator A5025991122 @default.
• W3048663323 creator A5036035882 @default.
• W3048663323 creator A5053317931 @default.
• W3048663323 creator A5058648892 @default.
• W3048663323 date "2020-08-11" @default.
• W3048663323 modified "2023-10-14" @default.
• W3048663323 title "Recombinant CCL17 Enhances Hematoma Resolution and Activation of CCR4/ERK/Nrf2/CD163 Signaling Pathway After Intracerebral Hemorrhage in Mice" @default.
• W3048663323 cites W1535567348 @default.
• W3048663323 cites W1984277325 @default.
• W3048663323 cites W2019167416 @default.
• W3048663323 cites W2024815543 @default.
• W3048663323 cites W2025878623 @default.
• W3048663323 cites W2038622171 @default.
• W3048663323 cites W2056034889 @default.
• W3048663323 cites W2064046777 @default.
• W3048663323 cites W2084943682 @default.
• W3048663323 cites W2091142824 @default.
• W3048663323 cites W2112161237 @default.
• W3048663323 cites W2121279023 @default.
• W3048663323 cites W2128479946 @default.
• W3048663323 cites W2129741568 @default.
• W3048663323 cites W2153960708 @default.
• W3048663323 cites W2158564443 @default.
• W3048663323 cites W2170225187 @default.
• W3048663323 cites W2216953671 @default.
• W3048663323 cites W2315695983 @default.
• W3048663323 cites W2330235342 @default.
• W3048663323 cites W2343778873 @default.
• W3048663323 cites W2409139088 @default.
• W3048663323 cites W2506572744 @default.
• W3048663323 cites W2553030829 @default.
• W3048663323 cites W2598198243 @default.
• W3048663323 cites W2601892519 @default.
• W3048663323 cites W2603525527 @default.
• W3048663323 cites W2604317173 @default.
• W3048663323 cites W2615735913 @default.
• W3048663323 cites W2756618289 @default.
• W3048663323 cites W2765390900 @default.
• W3048663323 cites W2809481702 @default.
• W3048663323 cites W2890847880 @default.
• W3048663323 cites W2892604754 @default.
• W3048663323 cites W2896796091 @default.
• W3048663323 cites W2904511486 @default.
• W3048663323 cites W2911625847 @default.
• W3048663323 cites W2912531099 @default.
• W3048663323 cites W2914769980 @default.
• W3048663323 cites W2935926710 @default.
• W3048663323 cites W2943246407 @default.
• W3048663323 cites W2963882251 @default.
• W3048663323 cites W2972804872 @default.
• W3048663323 cites W2982556924 @default.
• W3048663323 cites W2994864893 @default.
• W3048663323 cites W2996797923 @default.
• W3048663323 cites W2997022860 @default.
• W3048663323 cites W2997883682 @default.
• W3048663323 cites W2999488677 @default.
• W3048663323 cites W3171831654 @default.
• W3048663323 doi "https://doi.org/10.1007/s13311-020-00908-4" @default.
• W3048663323 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7851239" @default.
• W3048663323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32783091" @default.
• W3048663323 hasPublicationYear "2020" @default.
• W3048663323 type Work @default.
• W3048663323 sameAs 3048663323 @default.
• W3048663323 citedByCount "29" @default.
• W3048663323 countsByYear W30486633232021 @default.
• W3048663323 countsByYear W30486633232022 @default.
• W3048663323 countsByYear W30486633232023 @default.
• W3048663323 crossrefType "journal-article" @default.
• W3048663323 hasAuthorship W3048663323A5004014354 @default.
• W3048663323 hasAuthorship W3048663323A5010889678 @default.
• W3048663323 hasAuthorship W3048663323A5013900535 @default.
• W3048663323 hasAuthorship W3048663323A5016467704 @default.
• W3048663323 hasAuthorship W3048663323A5025991122 @default.
• W3048663323 hasAuthorship W3048663323A5036035882 @default.
• W3048663323 hasAuthorship W3048663323A5053317931 @default.
• W3048663323 hasAuthorship W3048663323A5058648892 @default.
• W3048663323 hasBestOaLocation W30486633231 @default.
• W3048663323 hasConcept C12823836 @default.
• W3048663323 hasConcept C13373296 @default.
• W3048663323 hasConcept C134678942 @default.
• W3048663323 hasConcept C141071460 @default.
• W3048663323 hasConcept C142724271 @default.
• W3048663323 hasConcept C143172330 @default.
• W3048663323 hasConcept C203014093 @default.
• W3048663323 hasConcept C2775866117 @default.
• W3048663323 hasConcept C2776914184 @default.
• W3048663323 hasConcept C2777094939 @default.
• W3048663323 hasConcept C2777736543 @default.
• W3048663323 hasConcept C2779662492 @default.
• W3048663323 hasConcept C2779727006 @default.
• W3048663323 hasConcept C42219234 @default.
• W3048663323 hasConcept C71924100 @default.

• next